The effect of funding sources on donepezil randomised controlled trial outcome: A meta-analysis

BMJ Open

Volumn 4, Issue 4, 2014, Pages

  Killin, Lewis O J ^a   Russ, Tom C ^a,b   Starr, John M ^a,b   Abrahams, Sharon ^a   Sala, Sergio Della ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b Scottish Dementia Clinical Research Network   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; MEMANTINE; PLACEBO; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE-COGNITIVE SUBSCALE; ARTICLE; CLINICAL TRIAL; COGNITION; DEMENTIA; DOWN SYNDROME; DRUG EFFECT; DRUG INDUSTRY; FUNDING; HUMAN; META ANALYSIS; MINI MENTAL STATE EXAMINATION; NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE; NEUROPSYCHOLOGICAL TEST; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; DRUG EFFECTS; ECONOMICS; FINANCIAL MANAGEMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ALZHEIMER DISEASE; COGNITION; HUMANS; INDANS; NEUROPSYCHOLOGICAL TESTS; NOOTROPIC AGENTS; PIPERIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH SUPPORT AS TOPIC; TREATMENT OUTCOME;

EID: 84899495331     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004083     Document Type: Article

References (41)

1. Callaway E. Alzheimer's drugs take a new tack. Nature 2012;489:13-14.
2. NICE. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease. 2011.
3. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004;363:2105-15.
4. Finucane T. Omitting donepezil is hardly a hardship. BMJ 2007;954. http://www.bmj.com/rapid-response/2011/11/01/omitting-donepezil-hardly-hardship
5. Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of TA111): a systematic review and economic model. Health Technol Assess 2012;16:1-470.
6. Loveman E, Green C, Kirby J, et al. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease. Health Technol Assess 2006;10:1-160.
7. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003;326:1167-70. (Pubitemid 36649048)
8. Baker CB, Johnsrud MT, Crismon ML, et al. Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 2003;183:498-506. (Pubitemid 37533195)
9. Tungaraza T, Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 2007;191:82-3. (Pubitemid 47035186)
10. Lundh A, Lexchin J, Sismondo S, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2012;12:MR000033.
11. Yuan Y, Hunt RH. Systematic reviews: the good, the bad, and the ugly. Am J Gastroenterol 2009;104:1086-92.
12. Cataldo JK, Prochaska JJ, Glantz SA. Cigarette smoking is a risk factor for Alzheimer's disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 2010;19:465-80.
13. Gilstad JR, Finucane TE. Results, rhetoric, and randomized trials: the case of donepezil. J Am Geriatr Soc 2008;56:1556-62.
14. Higgins JPT, Altman D, Gøtzsche P, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials. BMJ 2011;343:d5928.
15. R Development Core Team. R: a language and environment for statistical computing. 2008. http://www.r-project.org
16. Lumley T. rmeta 2012.
17. Homma A, Takeda M, Imai Y, et al. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2000;11:299-313.
18. Homma A, Imai Y, Tago H, et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008;25:399-407. (Pubitemid 351630073)
19. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial 1. Dement Geriatr Cogn Disord 1999;10:237-44. (Pubitemid 29224502)
20. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:481-8. (Pubitemid 32757597)
21. Tune L, Tiseo PJ, Ieni J, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. J Am Geriatr Soc 2003;11:169-77. (Pubitemid 36254190)
22. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95. (Pubitemid 32757598)
23. Higgins JPT, Green S.eds Cochrane handbook for systematic reviews of interventions version 5.0.2. The Cochrane Collaboration 2009. http://www.cochrane-handbook.org
24. Sedgwick P. Meta-analyses: heterogeneity and subgroup analysis. BMJ 2013;346:f4040.
25. Hempel S, Miles JNV, Booth MJ, et al. Risk of bias: a simulation study of power to detect study-level moderator effects in meta-analysis. Syst Rev 2013;2:107.
26. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct and reporting. BMJ 2010;340:c221.
27. Fries JF, Krishnan E. Equipoise, design bias, and randomized controlled trials: the elusive ethics of new drug development. Arthritis Res Ther 2004;6:R250-5.
28. Djulbegovic B, Lacevic M, Cantor A, et al. The uncertainty principle and industry-sponsored research. Lancet 2000;356:635-8. (Pubitemid 30627590)
29. Clemens F, Elbourne D, Derbyshire J, et al. Data monitoring in randomized controlled trials: surveys of recent practice and policies. Clin Trials 2005;2:22-33. (Pubitemid 40332925)
30. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol 2008;59:565-90.
31. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H-P, et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ 2005;331:321-7.
32. Seife C. Is drug research trustworthy? Sci Am 2012;307:56-63.
33. Roseman M, Milette K, Bero LA, et al. Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments. JAMA 2011;305:1008-17.
34. Greenberg SM, Tennis MK, Brown LB, et al. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 2000;57:94-9. (Pubitemid 30027636)
35. Mazza M, Capuano A, Bria P, et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study. Eur J Neurol 2006;13:981-5. (Pubitemid 44284905)
36. Winstein CJ, Bentzen KR, Boyd L, et al. Does the cholinesterase inhibitor, donepezil, benefit both declarative and non-declarative processes in mild to moderate Alzheimer's disease? Curr Alzheimer Res 2007;4:273-6. (Pubitemid 47025425)
37. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-19. (Pubitemid 38971117)
38. Maher-Edwards G, Dixon R, Hunter J, et al. SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int J Geriatr Psychiatry 2011;26:536-44.
39. Rogers S, Farlow M, Doody R, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998;50:291-8.
40. Rogers S, Doody R, Mohs R, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998;158:1021-31. (Pubitemid 28213580)
41. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neurol 2004;60:1852-6. (Pubitemid 39612945)